Cargando…

Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention

BACKGROUND: During the COVID pandemic, overall buprenorphine treatment appeared to remain relatively stable, despite some studies suggesting a decrease in patients starting buprenorphine. There is a paucity of empirical information regarding patterns of buprenorphine treatment during the pandemic. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein, Bradley D., Landis, Rachel K., Sheng, Flora, Saloner, Brendan, Gordon, Adam J., Sorbero, Mark, Dick, Andrew W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734477/ https://www.ncbi.nlm.nih.gov/pubmed/36474004 http://dx.doi.org/10.1007/s11606-022-07891-w

Ejemplares similares

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
por: Stein, Bradley D., et al.
Publicado: (2023)

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018
por: Golan, Olivia K., et al.
Publicado: (2023)

Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic
por: Alinsky, Rachel H., et al.
Publicado: (2022)

29. Use of Buprenorphine for Opioid Use Disorder among US Adolescents and Young Adults During the COVID-19 Pandemic
por: Alinsky, Rachel, et al.
Publicado: (2022)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021
por: Thakrar, Ashish P., et al.
Publicado: (2021)

Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
por: Geist, Mary L., et al.
Publicado: (2023)

Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
por: Solomon, Keisha T., et al.
Publicado: (2023)

Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic
por: Cantor, Jonathan, et al.
Publicado: (2021)

Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19
por: Samuels, Elizabeth A., et al.
Publicado: (2022)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database
por: Saloner, Brendan, et al.
Publicado: (2021)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Patient’s perspective on early treatment retention in take home buprenorphine maintenance treatment- an explorative study from India
por: M, P., et al.
Publicado: (2021)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Implementing a Novel Statewide Network to Support Emergency Department-initiated Buprenorphine Treatment
por: Clemency, Brian M., et al.
Publicado: (2022)

Criminal charges prior to and after initiation of office-based buprenorphine treatment
por: Harris, Elizabeth E, et al.
Publicado: (2012)

Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy
por: Nguyen, Andrea, et al.
Publicado: (2023)

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
por: Sweeney, Mary M., et al.
Publicado: (2022)

Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019
por: Andraka-Christou, Barbara, et al.
Publicado: (2023)

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study
por: Suarez, Edward, et al.
Publicado: (2023)

A national survey of state laws regarding medications for opioid use disorder in problem-solving courts
por: Andraka-Christou, Barbara, et al.
Publicado: (2022)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Advancing emergency department–initiated buprenorphine
por: Huntley, Kristen, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

Prior criminal charges and outcomes among individuals initiating office-based buprenorphine treatment
por: Harris, Elizabeth E, et al.
Publicado: (2013)

Physicians’ satisfaction with providing buprenorphine treatment
por: Knudsen, Hannah K., et al.
Publicado: (2019)

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
por: Duncan, Alexandra, et al.
Publicado: (2020)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program
por: Parran, Theodore V, et al.
Publicado: (2017)

Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder
por: Berry, Amanda R. W., et al.
Publicado: (2021)

Malmö Treatment Referral and Intervention Study—High 12-Month Retention Rates in Patients Referred from Syringe Exchange to Methadone or Buprenorphine/Naloxone Treatment
por: Bråbäck, Martin, et al.
Publicado: (2017)

Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
por: Chen, Annie Y., et al.
Publicado: (2022)

Community Treatment Programs Take Up Buprenorphine
por: Casadonte, Paul P., et al.
Publicado: (2004)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

Buprenorphine and pain treatment in pediatric patients: an update
por: Vicencio-Rosas, Erendira, et al.
Publicado: (2018)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
por: Furo, Hiroko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p0n4gbgp71smnrr2am1vmqlksh